Mohamed Elsayed

Dr. Mohamed ElSayed is the Chief Technology Officer at RVAC. He is an accomplished leader with over 25 years of experience spanning academic, biotechnology, and pharmaceutical organizations. He has deep expertise in the development of innovative delivery technologies for nucleic acids, biologics, bioconjugates, and small molecules. Prior to RVAC, Dr. ElSayed held positions of increasing responsibilities at Eli Lilly & Company where he established the Oral Peptides Delivery Platform and led the discovery and preclinical development of multiple oral biologics. He is a recognized expert in the development of nucleic acid therapies. Earlier in his career, Dr. ElSayed was a tenured professor at the University of Michigan and served as an advisor for multiple biopharmaceutical companies; he received a Ph.D. in Pharmaceutical Sciences from the University of Maryland in Baltimore.